High plasma level human soluble type plasminogen is associated with poor clinical outcomes and focal segmental glomerulosclerosis. When the level of urokinase-type plasminogen increases, it causes severe kidney problem and hampers the functioning of the organ.

Human Soluble urokinase-type plasminogen is expressed on various cell types that include lymphocytes, macrophage, and neutrophils. This urokinase-type plasma activator involves various types of biological functions. In the diagnosis of cancer, uPAR and uPA play a key role in converting plasminogen into plasmin that ultimately leads to the degradation of extracellular matrix.

It is basically a thrombolytic agent that works on dissolving blood clots. This particular element is used in treating blood clots in the lungs. However, if you have internal bleeding, aneurysm or brain tumor, or if you recently had a stroke, spinal surgery or brain problem, you should not use this medicine. Urokinase is made from albumin and human kidney cells that contain infectious agents and viruses. The donated plasma is treated for reducing the risk associated with various infectious agents.

Urokinase-type plasminogen is used as an injection into a vein. It is pushed very slowly, basically over a period of 12 hours which is used a continuous infusion pump. The breathing system, blood pressure, oxygen level and other vital signs are closely taken into consideration while providing urokinase.